Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Harvard Announces $50 Million Gift from the Blavatnik Family Foundation

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Blavatnik Biomedical Accelerator will be a catalyst to transform basic scientific discoveries into new therapies and cures.

The Blavatnik Family Foundation, headed by Len Blavatnik (M.B.A. ’89), has donated $50 million to Harvard University. The gift will launch a major initiative to expedite the development of basic science discoveries into new breakthrough therapies for patients and cures for disease. The gift underpins Harvard’s growing commitment to creating an entrepreneurial culture in the life sciences.

Support for early-stage research and new inventions is vital to bridge the most challenging obstacle in university technology development, known as the “development gap”—the period of validating and building value around early-stage technologies, making them ripe for partnering with industry. The Blavatnik Biomedical Accelerator will identify early-stage, highly promising technologies, upgrade their value, and prepare them for licensing and commercial development.

The gift will also create the Blavatnik Fellowship in Life Science Entrepreneurship Program at Harvard Business School (HBS) to provide MBA students with experience in life science entrepreneurship through exposure to the biomedical projects supported by the Accelerator.

Len Blavatnik, a longtime supporter of Harvard and a widely respected business leader, entrepreneur, and philanthropist, is well known for his interest and investments in the nexus between scientific innovation and business. Through the Blavatnik Family Foundation, he has supported leading educational, scientific, cultural, and charitable institutions throughout the world, including the University’s original 2007 Biomedical Accelerator Fund.

“By partnering with Harvard’s world-class biomedical research division, I am delighted to help accelerate the development of new therapies,” said Mr. Blavatnik. “Moreover, by increasing the collaborative efforts between Harvard Business School and Harvard’s scientific community, we will empower the next generation of life science entrepreneurs and provide a further catalyst for innovation and research development.”

In welcoming the $50 million gift, Harvard President Drew Faust highlighted Mr. Blavatnik’s commitment to innovation and transformational science. “Len Blavatnik’s passionate support of entrepreneurship and science as forces for progress reflects the forward-thinking leadership that will allow Harvard and others to develop promising new technologies that benefit society as a whole,” said Faust. “The Blavatnik Biomedical Accelerator and the integrated cross-university partnership it enables will advance the next great breakthroughs in biomedical technology, with its roots at Harvard.”

HBS Dean Nitin Nohria added, “By bringing together expertise and experience from across Harvard, the Accelerator and the HBS Fellows program will further enhance Harvard’s commitment to innovative research and entrepreneurship. With student interest in entrepreneurship at an all-time high and with the resources of the University’s Innovation Lab and HBS’s Arthur Rock Center for Entrepreneurship at the ready, we are well positioned to make the most of this generous gift from the Blavatnik Family Foundation.”

The Blavatnik Biomedical Accelerator will be operated within the University’s Office of Technology Development. It builds upon the success of the first Biomedical Accelerator Fund— created five years ago by Isaac T. Kohlberg, the University’s senior associate provost and chief technology officer—which was also funded in part with support from the Blavatnik Family Foundation. The original Accelerator Fund has funded 37 projects, half of which are already advancing through alliances with biopharmaceutical partners or the creation of new companies. The expanded Accelerator program will focus particularly on therapeutic opportunities. It is structured to become self-sustaining, ensuring that over the long term, Harvard will remain at the forefront of life science research.

“The Blavatnik Biomedical Accelerator will enhance the value proposition of early-stage technologies and expedite the flow of Harvard inventions through key developmental milestones and into the marketplace,” said Kohlberg. “Some of the most important therapies and technologies in existence today originated from alliances between academia and the life sciences industry, and we look forward to many more in the years ahead.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Thursday, October 01, 2015
Delivering Hope in Ovarian Cancer
Gene therapy blocked chemoresistant tumor growth in mice.
Tuesday, August 11, 2015
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Monday, July 27, 2015
The Secrets of Secretion
Researchers have hacked nature's blueprints to create a new technology that could have broad-reaching impact on drug delivery systems and self-healing and anti-fouling materials.
Tuesday, June 23, 2015
Beyond Average
Researchers have created new platforms to genetically barcode tens of thousands of cells at a time allowing unprecedented detail to be uncovered when studying whole tissue samples.
Tuesday, May 26, 2015
One Molecule at a Time
The ability to study single molecules provides tangible targets for personalised medicine.
Monday, May 18, 2015
New Technique Diagnoses Cancer from Bodily Fluids
Harvard researchers contributed machine learning techniques to improve UCLA diagnostic tool.
Tuesday, November 26, 2013
Malaria in 3-D
Advanced imaging aids study of cell movement.
Tuesday, November 26, 2013
A Marker for Breast Cancer
Research says it soon may be possible to gauge individual risk for disease, and eventually to treat it.
Tuesday, August 13, 2013
Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos